Itonic Holdings Ltd. (NASDAQ:ITOC) Short Interest Down 33.7% in May

Itonic Holdings Ltd. (NASDAQ:ITOC) saw a significant decline in short interest in the month of May. As of May 29th, there was short interest totaling 197,966 shares, a decline of 33.7% from the May 14th total of 298,627 shares. Based on an average daily volume of 48,103 shares, the short-interest ratio is presently 4.1 days. Currently, 1.2% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Itonic from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 5th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Itonic Stock Up 0.9%

Shares of NASDAQ ITOC traded up $0.00 during midday trading on Wednesday, hitting $0.36. The company’s stock had a trading volume of 6,885,419 shares, compared to its average volume of 2,894,363. The company’s fifty day simple moving average is $0.32. Itonic has a one year low of $0.25 and a one year high of $32.00.

Itonic (NASDAQ:ITOC) last announced its quarterly earnings results on Monday, March 30th. The company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $0.23 million for the quarter.

Itonic Company Profile

iTonic Holdings Ltd., a healthcare solutions provider, develops and commercializes treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a radioactive particle implantation, a radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company offers FTTPS, a treatment planning system for treating various malignant tumors, which could determine the target volume, prescription dose, and dose limitation to protect organs at risks and produce dose distribution plan for brachytherapy for cancer patients.